UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36687 XENON PHARMACEUTICALS INC. WASHINGTON, D.C. 20549 FORM 10‑Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR Canada 98-0661854 (State or other jurisdiction of incorporation or organization) 200-3650 ...

Xenon Pharmaceuticals, Inc. (NASDAQ:XENE) Q2 2019 Earnings Conference Call August 6, 2019 4:30 PM ET Company Participants Jodi Regts - IR Simon Pimstone - CEO & Director Ian Mortimer - President, CFO, COO & Company Secretary Conference Call Participants Alex Thompson - Stifel Swapnil Malekar - Jefferies Antonia Borovina - Bloom Burton & Co. Operator Good day, ladies and gentlemen, and welcome to the Second Quarter 2019 Xenon Pharmaceuticals Earnings Conference Call. [Operator Instructions]. As a reminder, t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10‑Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36687 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in its Charter) Canada 98-0661854 (State or other jurisd ...

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q1 2019 Earnings Conference Call May 7, 2019 4:30 PM ET Company Participants Jodi Regts - VP, Corporate Affairs and IR Simon Pimstone - CEO Ian Mortimer - President and CFO Conference Call Participants Paul Matteis - Stifel David Martin - Bloom Burton Operator Good day, ladies and gentlemen, and welcome to the Q1 2019 Xenon Pharmaceuticals Inc. Earnings Conference Call. [Operator Instructions]. As a reminder, this conference call is being recorded. I would now like t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10‑Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36687 XENON PHARMACEUTICALS INC. Indicate by check mark whether the registrant (1) has filed all reports required to be filed b ...

Xenon Pharmaceuticals (NASDAQ:XENE) Q4 2018 Results Earnings Conference Call March 6, 2019 4:30 PM ET Company Participants Jodi Regts - VP, Corporate Affairs and IR Simon Pimstone - CEO Ian Mortimer - President and CFO Conference Call Participants Stephen Willey - Stifel Maurice Raycroft - Jefferies Operator Good day, ladies and gentlemen, and welcome to the Fourth Quarter 2018 Xenon Pharmaceuticals Incorporated Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call i ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36687 XENON PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorporation ...